Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular Targeted Agents and Biologic Therapies for Lung Cancer

Molecular Targeted Agents and Biologic Therapies for Lung Cancer SANTA MONICA SUPPLEMENT Summary of Presentation from the Targeted Therapy in Lung Cancer Meeting Ramaswamy Govindan, MD ust like every year over the past decade, leading experts Abstract: New pathways are being identified now on a regular Jwith special research interest in lung cancer from around basis, and novel agents are being tested in a wide variety of the world met again a few months ago in Santa Monica, clinical trials for patients with advanced non-small cell lung California, to discuss strategies for improving the outcomes cancer. Excitement over progress in one area is tempered natu- of patients with lung cancer using molecularly targeted ther- rally by disappointing results in other areas. Each year, leading apies. As has been made clear before, this is a large “work in lung cancer experts meet in Santa Monica to discuss the progress progress” meeting. New pathways are being identified now in the field of molecularly targeted therapy in non-small cell lung on a regular basis, and novel agents are being tested in a wide cancer. Annual conferences similar to the one held in Santa variety of clinical trials for patients with advanced non-small Monica serve mainly as a catalyst to promote new http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Molecular Targeted Agents and Biologic Therapies for Lung Cancer

Journal of Thoracic Oncology , Volume 6 – Nov 1, 2011

Loading next page...
 
/lp/wolters-kluwer-health/molecular-targeted-agents-and-biologic-therapies-for-lung-cancer-3sjPIivCPV

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

SANTA MONICA SUPPLEMENT Summary of Presentation from the Targeted Therapy in Lung Cancer Meeting Ramaswamy Govindan, MD ust like every year over the past decade, leading experts Abstract: New pathways are being identified now on a regular Jwith special research interest in lung cancer from around basis, and novel agents are being tested in a wide variety of the world met again a few months ago in Santa Monica, clinical trials for patients with advanced non-small cell lung California, to discuss strategies for improving the outcomes cancer. Excitement over progress in one area is tempered natu- of patients with lung cancer using molecularly targeted ther- rally by disappointing results in other areas. Each year, leading apies. As has been made clear before, this is a large “work in lung cancer experts meet in Santa Monica to discuss the progress progress” meeting. New pathways are being identified now in the field of molecularly targeted therapy in non-small cell lung on a regular basis, and novel agents are being tested in a wide cancer. Annual conferences similar to the one held in Santa variety of clinical trials for patients with advanced non-small Monica serve mainly as a catalyst to promote new

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Nov 1, 2011

There are no references for this article.